oral rinse

University of Cincinnati researcher studies cancer-detecting mouthwash with help from ACS grant

Source: healthnews.uc.edu Author: staff Scott Langevin, PhD, assistant professor in the Department of Environmental Health and a member of both the Cincinnati Cancer Center (CCC) and UC Cancer Institute, was recently awarded $782,000 from the American Cancer Society to continue his research, which will hopefully assist in use of a certain oral rinse to catch recurrence of these types of cancers in their earliest stages. He originally received a National Cancer Institute K22 award to begin this study. "In 2017, mouth and throat cancer, otherwise known as oral and pharyngeal cancer, accounted for an estimated 49,670 new cancer diagnoses and 9,700 cancer-related deaths in the US, and the outcomes for patients with this cancer is relatively poor. About half of these patients will have cancer recurrence within 2 years of treatment,” Langevin says. "Earlier detection of recurrent tumors is associated with better clinical outcomes, so there is a clear need for new tests that can help facilitate early detection.” Langevin says that researchers in his lab previously identified a biomarker panel made up of 22 regions of DNA; based on the amount of a certain molecule attached to these regions—a process called DNA methylation—scientists could identify the presence of mouth and throat cancer with a high level of accuracy by using noninvasive oral rinse (mouthwash) samples. "With this project, we hope to evaluate the potential of this oral rinse methylation panel as a clinical tool for early detection of cancer recurrence following diagnosis and treatment,” he says. "This will hopefully [...]

Oral Cancer Foundation News Team - A2018-10-23T12:24:47-07:00October, 2018|Oral Cancer News|

HPV DNA detected in mouthwash predicts oral cancer recurrence

Source: www.onclive.com Author: Kelly Johnson The presence of HPV16 DNA is common at diagnosis of HPV-related oropharyngeal carcinoma (HPV-OPC) but rare after treatment. HPV-OPC has a favorable prognosis; however, 10% to 25% of patients experience disease progression, usually within 2 years of treatment. Patients who have HPV 16 DNA in their saliva following treatment of their oropharyngeal cancer are more likely to have their cancer recur, and a prospective cohort study published in JAMA Oncology has shown that a simple mouth rinse can be used to detect it. Gypsyamber D’Souza Gypsyamber D’Souza, PhD, Johns Hopkins Bloomberg School of Public Health, and fellow researchers monitored 124 patients with newly diagnosed oropharyngeal cancer from 2009 through 2013. They collected oral rinse and gargle samples using 10 mL of mouthwash at the time of diagnosis as well as after treatment 9, 12, 18, and 24 months later. HPV16 DNA was detected in 67 out of 124 of the participants testing positive. Of the 67 patients who had HPV16 DNA in their saliva at the time of diagnosis, five patients (7%) were found to still have traces of HPV16 in their oral rinses following treatment. All five patients developed a local recurrence of oropharyngeal cancer, three of whom died from the disease. “It’s a very small number so we have to be somewhat cautious,” said D’Souza, an associate professor in the Department of Epidemiology at the Bloomberg School and a member of the Sidney Kimmel Comprehensive Cancer Center, in a statement. However, [...]

Oral Cancer Foundation News Team - A2015-08-27T14:25:55-07:00August, 2015|Oral Cancer News|

Oral rinses used for tracking HPV-positive head and neck cancers hold promise for screening

Source: American Association for Cancer Research Author: staff A study published in the journal Clinical Cancer Research, a journal of the American Association for Cancer Research, validates a non-invasive screening method with future potential for detection of human papillomavirus (HPV)-positive head and neck cancers. In the study, researchers at Johns Hopkins University used oral rinses and targeted DNA amplification to track and identify oral HPV infections in patients with HPV16-positive and negative head and neck carcinomas (HNSCC) before and after therapy. Findings showed detection of high-risk HPV infections in patients with HPV16-positive HNSCC for up to five years after therapy, indicating a high rate of persistent infection and reaffirming the connection between high-risk types of HPV and HPV-positive head and neck cancer. “There is no question of cause,” said the study’s co-author Maura Gillison, M.D., Ph.D. associate professor of oncology. “It has now become a question of tracking the infection over time to identify those at risk of developing HPV-positive cancer, and for those who have had it, the risk of recurrence and risk of transmission. This is the first study in which we have been able to track the disease and related oral infections for an extended period of time.” Researchers obtained oral rinse samples from a group of 135 patients with head and neck carcinomas. Tissue analysis showed that 44 of these patients had HPV16-positive tumors. Both the tissue and oral rinse samples were genetically sequenced to specify the HPV variants in each. Patients with HPV16-positive tumors were [...]

Oral Cancer Foundation News Team - A2008-12-29T22:53:40-07:00December, 2008|Oral Cancer News|

Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening

Source: www.eurekalert.com Author: staff A study published in the journal Clinical Cancer Research, a journal of the American Association for Cancer Research, validates a non-invasive screening method with future potential for detection of human papillomavirus (HPV)-positive head and neck cancers. In the study, researchers at Johns Hopkins University used oral rinses and targeted DNA amplification to track and identify oral HPV infections in patients with HPV16-positive and negative head and neck carcinomas (HNSCC) before and after therapy. Findings showed detection of high-risk HPV infections in patients with HPV16-positive HNSCC for up to five years after therapy, indicating a high rate of persistent infection and reaffirming the connection between high-risk types of HPV and HPV-positive head and neck cancer. "There is no question of cause," said the study's co-author Maura Gillison, M.D., Ph.D. associate professor of oncology. "It has now become a question of tracking the infection over time to identify those at risk of developing HPV-positive cancer, and for those who have had it, the risk of recurrence and risk of transmission. This is the first study in which we have been able to track the disease and related oral infections for an extended period of time." Researchers obtained oral rinse samples from a group of 135 patients with head and neck carcinomas. Tissue analysis showed that 44 of these patients had HPV16-positive tumors. Both the tissue and oral rinse samples were genetically sequenced to specify the HPV variants in each. Patients with HPV16-positive tumors were significantly more likely to [...]

Oral Cancer Foundation News Team - A2008-10-31T07:32:31-07:00October, 2008|Oral Cancer News|